Cardiac Death, Cardiac Death, Sudden, Wolf Parkinson White Syndrome
Conditions
Keywords
accessory pathway, ablation, cardiac death, Wolf Parkinson's white
Brief summary
The investigators propose a secondary chart review using EMR data to identify risk factors for sudden cardiac death in active-duty members diagnosed with an accessory pathway between the ages of 18-40.
Detailed description
The LEAD-AP study is a dual arm retrospective observational cohort study (using existing records) to investigate the long-term outcomes of patients diagnosed with an accessory pathway during their military service. Overall objective: Identifying additional risk factors associated with sudden cardiac death to help with risk stratification and guide ablation criteria for patients diagnosed with accessory pathways between the ages of 18-40. Specific Aim/Research Question: The investigators will evaluate whether patients with an ablation have improved outcomes.
Interventions
PROCEDUREAblation
Patient treated with an ablation to eliminate the accessory conduction pathway in the heart.
PROCEDUREStandard of care without ablation
Patient diagnosed with accessory pathway but elected against cardiac ablation as a treatment option at the time of diagnosis.
Sponsors
United States Naval Medical Center, San Diego
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Active Duty between ages 18-40 who were diagnosed with an accessory pathway between 1/1/1990 - 5/30/2024.
Exclusion criteria
* Patient without the diagnosis of Wolf Parkinson's White (WPW) syndrome
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac death | 5 years | The goal of LEAD AP is to investigate the long-term outcomes of patients diagnosed with an accessory pathway during their military service; with the goal of identifying additional risk factors associated with sudden cardiac death to help with risk stratification and guide ablation for patients diagnosed with accessory pathways between the ages of 18-40. |
Countries
United States
Outcome results
None listed